Pharmalundensis AB is engaged in the development of pharmaceuticals aimed at binding and excreting heavy metals, such as mercury, lead, and cadmium, from the human body. The company focuses on potential health improvements for various diseases, with a particular emphasis on chronic obstructive pulmonary disease (COPD). One of its notable products, Phal-501, has shown promise as a transformative medication for patients suffering from severe COPD, supported by positive results from animal toxicology tests.
The company has also published a patent application for Phal-501, which has yielded favorable outcomes. In addition to its pharmaceutical development, Pharmalundensis AB has recently raised approximately 3.13 million SEK in capital. The organization provides quarterly reports that offer insights for investors, along with updates on the sales of mini-evaporators. Furthermore, the company is conducting research comparing AstraZeneca's Fasenra to a placebo in the context of COPD treatment.